Global Genomics Partners With Sanofi To Find Out Etiology Of Cornonary Diseases

(RTTNews) - Global Genomics Group Tuesday said it has entered into a research collaboration with Sanofi (SNYNF, SNY) to identify new signaling pathways and targets involved in the etiology of coronary artery disease. The companies have not disclosed the financial aspects of the collaboration.

As per the agreement, Sanofi and G3 will utilize G3's proprietary platform with data from its G3LOBAL Database to further unravel the molecular underpinnings of LDL-cholesterol regulation. It will help in understanding molecular networks behind human diseases and would help in drug discovery and development.

Szilard Voros, founder and chief executive officer of G3 said, "We believe that precision phenotyping, pan-omics and systems-biology driven bioinformatics are the key components of target identification, validation and the elucidation of novel pathways."